Geographical, climatological, biologic and clinical patients characteristics
| No cutaneous manifestations | Cutaneous manifestations | p | |
|---|---|---|---|
| Age, year ± SD | 49,3 ± 15.9 | 46.2 ± 13.9 | 0,000 |
| Disease duration (last visit to onset SLE), median (interqualite range), months | 95.5 (48.2–151.5) | 133.0 (70.8–213.2) | 0,921 |
| Global radiation, mean daily radiation ± SD | 1620.0 ± 175.1 | 1620.9 ±193.9 | 0.902 |
| Ultraviolet radiations, mean daily radiation ± SD | 2416.7 ± 449.9 | 2446.6 ± 481.4 | 0.202 |
| Hours of Sun, year mean ± SD | 2144.9 ± 290.9 | 2149.4 ± 328.8 | 0.757 |
| Temperature, mean monthly ± SD | 15.2 ± 3.5 | 15.3 ± 3.6 | 0.629 |
| Humidity, relative mean ± SD | 2416.7 ± 449.9 | 2416.7 ± 449.9 | 0.138 |
| N=495 | N=2424 | p | |
| Sex: female, n (%) | 405 (81.8) | 2251 (92.8) | 0.000 |
| Current smoking: n (%) | 61 (12.3) | 383 (15.8) | 0.062 |
| South area, n (%) | 376 (75.9) | 1746 (72.0) | 0.065 |
| Coastal regions, n (%) | 277 (55.9) | 1231 (50.7) | 0.033 |
| Caucasican, n (%) | 437 (88.2) | 2198 (90.6) | 0.118 |
| Latinoamericam, n (%) | 31 (6.2) | 118 (4.8) | 0.189 |
| Arthritis, n (%) | 402 (81.2) | 1862 (76.8) | 0,018 |
| Serositis, n (%) | 178 (35.9) | 609 (25.1) | 0,000 |
| Renal disorder, ever, n (%) | 139 (28.0) | 689 (28.4) | 0.861 |
| Retina disorder, ever, n (%) | 12 (2.4) | 121 (5.0) | 0.540 |
| Hemolytic anemia, n (%) | 26 (5.2) | 103 (4.2) | 0,371 |
| Leucopenia, n (%) | 272 (54.9) | 1466 (60.4) | 0.010 |
| Lymphopenia, n (%) | 279 (56.3) | 1252 (51.6) | 0.051 |
| Thrombocytopenia, n (%) | 101 (20.4) | 524 (21.6) | 0.508 |
| Antiphospholipids antibodies, n (%) | 217 (43.8) | 875 (36.1) | 0.001 |
| Anti DNA, n (%) | 401 (81.0) | 1704 (70.2) | 0.000 |
| Anti Sm, n (%) | 102 (20.6) | 513 (21.1) | 0.728 |
| Anti-Ro/SSA, n (%) | 158 (31.9) | 982 (40.5) | 0.000 |
| Anti-La/SSB, n (%) | 71 (14.3) | 501 (20.6) | 0.001 |
| Hypocomplementemia, n (%) | 362 (73.1) | 1867 (77.0) | 0.072 |
| SELENA-SLEDAI, median (interquartile range) | 2 (0–3) | 2 (0–4) | 0.990 |
| SLICC/ACR-DI, median (interquartile range) | 0 (0–1) | 1 (0–1) | 0.252 |
| Katz severity index, median (interquartile range) | 2 (1–3) | 2 (1–3) | 0.900 |
| Glucocorticoids, ever, n (%) | 403 (81.4) | 2046 (84.4) | 0.474 |
| Antimalarial drug: ever, n (%) | 371 (74.9) | 2036 (84.0) | 0.000 |